MTAP loss and key alteration detection via liquid biopsy explored in #BladderCancer. @CMercinelli@MyUniSR joins @UroDocAsh@UTMDAnderson to discuss liquid biopsy detection of MTAP loss in bladder cancer. Liquid biopsies provide non-invasive serial monitoring throughout treatment lines, enabling treatment decision guidance for metastatic disease without requiring archived tissue specimens. #WatchNow on UroToday > bit.ly/4cLY8Xv
#ASCOGU2026 Rapid orals
The amazing @AndreaNecchi rocks the stage with SunRise 2 trial in MIBC.
Pragmatic trial of Gem-iDRS cetrelimab vs concurrent CRT, no improvement in BI-EFS vs CRT. Trial stopped early. 1st trial with CRT in experimental arm.
CRT continues as standard for now.
@OncoAlert@Uromigos
The standard of care for MIBC will now include perioperative EVP for both cisplatin eligible and ineligible #BladderCancer pts. The EV304 study presented today @MattGalsky shows an improvement in EFS (HR 0.53) and OS (HR 0.65) for EVP over GC. @ASCO#GU26
At @SanRaffaeleMI#GURetreat25 organized by @AndreaNecchi@SpiessPhilippe gives an outstanding overview of his and Andrea's brainchild @GTumors during Covid.
What a massive growth & 🌏 outreach the society has achieved with its efforts in education, patient outreach, retrospective data analysis, tumor boards, pathology, genomics young oncologists and much more.
Grateful to be a part of this tremendous initiative!
@AndreaNecchi does a phenomenal job highlighting the explosive growth in bladderca treatment & biomarker landscape with cDNA
He is a trailblazer leading the way with next gen IITs
@SanRaffaeleMI#GURetreat25@BrigidaMaiorano
Honored to be at the FOURTH @SanRaffaeleMI#UrologicOncology Retreat, hosted by the inimitable @AndreaNecchi. He has done a phenomenal job of bringing leaders in GU #oncology from around the world to exchange ideas & develop guidelines.